Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,785.00
-75.00 (-1.94%)
Mar 28, 2025, 3:30 PM KST
-69.67%
Market Cap 41.40B
Revenue (ttm) 1.95B
Net Income (ttm) -9.79B
Shares Out 10.94M
EPS (ttm) -1,025.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 116,487
Average Volume 97,833
Open 3,860.00
Previous Close 3,860.00
Day's Range 3,690.00 - 3,870.00
52-Week Range 3,385.00 - 12,900.00
Beta n/a
RSI 34.60
Earnings Date Mar 28, 2025

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 61
Stock Exchange KOSDAQ
Ticker Symbol 373110
Full Company Profile

Financial Performance

In 2023, Xcell Therapeutics's revenue was 1.12 billion, an increase of 10.18% compared to the previous year's 1.02 billion. Losses were -9.28 billion, 11.2% more than in 2022.

Financial Statements

News

There is no news available yet.